Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 9.8% – Here’s What Happened

Posted by George Bondi on May 22nd, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shares rose 9.8% during mid-day trading on Friday . The company traded as high as $4.11 and last traded at $4.0620. Approximately 6,380,841 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 14,991,732 shares. The stock had previously closed at $3.70.

Analyst Ratings Changes

IOVA has been the subject of a number of research analyst reports. Chardan Capital reduced their target price on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 target price for the company in a report on Tuesday, March 3rd. The Goldman Sachs Group restated a “sell” rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. Finally, UBS Group increased their target price on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.43.

Check Out Our Latest Stock Analysis on IOVA

Iovance Biotherapeutics Stock Up 11.2%

The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -4.34 and a beta of 0.69. The stock’s 50 day moving average price is $3.65 and its two-hundred day moving average price is $3.04.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The business had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. During the same period in the prior year, the business posted ($0.36) earnings per share. Iovance Biotherapeutics’s revenue for the quarter was up 44.9% compared to the same quarter last year. On average, equities analysts expect that Iovance Biotherapeutics, Inc. will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of hedge funds have recently modified their holdings of IOVA. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Iovance Biotherapeutics during the third quarter worth $27,000. Arcataur Capital Management LLC bought a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $29,000. Granite Investment Partners LLC bought a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $29,000. Motley Fool Asset Management LLC bought a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $29,000. Finally, M&T Bank Corp bought a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $31,000. 77.03% of the stock is owned by institutional investors and hedge funds.

About Iovance Biotherapeutics

(Get Free Report)

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.